Hepatitis B Virus Reactivation Risk Varies with Different Chemotherapy Regimens Commonly Used in Solid Tumours
Overview
Authors
Affiliations
Background: Hepatitis B virus (HBV) reactivation may occur with chemotherapy and has significant morbidity and mortality. The United States Centre for Disease Control and Prevention recommends pre-chemotherapy hepatitis B screening for all cancer patients, while the American Society of Clinical Oncology finds that there is insufficient evidence currently to support such a recommendation. Apart from anthracyclines, HBV reactivation rates from other commonly used chemotherapy regimens in solid tumours are not well described.
Methods: We compared HBV reactivation risk in patients receiving several commonly used chemotherapy regimens for solid tumours associated with different immunosuppression risk at a tertiary cancer centre in an HBV endemic region.
Results: A total of 1149 patients were identified, including 434, 196, 245 and 274, respectively, who received doxorubicin-based, oxaliplatin- or irinotecan-based, carboplatin/gemcitabine, and capecitabine chemotherapy. HBV screening rate was 39% overall. Thirty out of 448 (7%) screened patients were HBsAg positive and 28 out of 30 received prophylactic antiviral therapy with no reactivation. Three out of 1149 patients overall (0.3%) developed HBV reactivation, all from the unscreened doxorubicin group (3 out of 214, 1.4%). No unscreened patients (0 out of 487) in the other three treatment groups developed reactivation (P<0.001).
Conclusion: Not all chemotherapy regimens result in HBV reactivation. Routine hepatitis B screening for low- or moderate-risk regimens may not be warranted.
Shih C, Chen W World J Clin Cases. 2021; 9(21):5769-5781.
PMID: 34368296 PMC: 8316946. DOI: 10.12998/wjcc.v9.i21.5769.
Neulinger-Munoz M, Schaack D, Grekova S, Bauer A, Giese T, Salg G Viruses. 2021; 13(6).
PMID: 34071585 PMC: 8228339. DOI: 10.3390/v13061019.
Risk factors for hepatitis B during solid cancer treatment.
Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y World J Clin Cases. 2021; 8(24):6264-6273.
PMID: 33392307 PMC: 7760444. DOI: 10.12998/wjcc.v8.i24.6264.
Zhang X, Liang Y, Li X, Wang W, Tong J, Xu Y Medicine (Baltimore). 2020; 99(40):e22642.
PMID: 33019490 PMC: 7535632. DOI: 10.1097/MD.0000000000022642.
Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.
Smalls D, Kiger R, Norris L, Bennett C, Love B Pharmacotherapy. 2019; 39(12):1190-1203.
PMID: 31596963 PMC: 6893091. DOI: 10.1002/phar.2340.